- Coordinator
- Johann Wolfgang Goethe-Universitaet Frankfurt Am Main, Germany
- Runs
- 1 June 2026 to 31 May 2031
- Status
- Running
- EU funding
- €15.2m
- Total cost
- —
- Partners
- 16 organisations in 8 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101287159
What the project is doing
In the project's own words, from its summary on CORDIS.
Recurrent urinary tract infections (rUTIs) impose a substantial clinical and socio-economic burden, particularly in women, and are increasingly complicated by antimicrobial resistance (AMR). Current treatment options rely heavily on antibiotics, fueling resistance and limiting therapeutic efficacy. The REPhRAME project addresses this unmet need by evaluating innovative, non-antibiotic strategies: a bacteriophage-based investigational medicinal product for acute treatment, and fecal microbiota transplantation (FMT-IMP) to prevent recurrence.
Building on a seamless Phase Ib/IIa randomized controlled trial, the study will determine optimal routes of administration, assess efficacy in reducing antibiotic use, and evaluate recurrence prevention. Multi-omics analyses, biomarker discovery, and health economic modelling complement the clinical trial, while patient engagement, ethical oversight, and regulatory alignment ensure societal relevance and translational impact.
By integrating precision medicine, novel biologics manufacturing, and robust clinical evidence, REPhRAME aims to pioneer sustainable alternatives to antibiotics, improving quality of life and supporting EU goals in AMR mitigation and healthcare innovation.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Johann Wolfgang Goethe-Universitaet Frankfurt Am Main | Frankfurt Am Main | Germany | Coordinator |
| Sib Swiss Institute of Bioinformatics | Genf | Switzerland | Participant |
| Universitaet Bern | Bern | Switzerland | Participant |
| Universitat Zurich | Zurich | Switzerland | Participant |
| Deutsches Zentrum Fur Infektionsforschung (dzif) eV | Braunschweig | Germany | Participant |
| Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eV | Munchen | Germany | Participant |
| Klinikum Der Universitaet Zu Koeln | Koeln | Germany | Participant |
| Linq Management GmbH | Berlin | Germany | Participant |
| Medizinische Hochschule Hannover | Hannover | Germany | Participant |
| Snipr Biome Aps | Copenhagen O | Denmark | Participant |
| HUN-REN Szegedi Biologiai Kutatokozpont | Szeged | Hungary | Participant |
| Rigas Stradina Universitate | Riga | Latvia | Participant |
| Academisch Ziekenhuis Leiden | Leiden | Netherlands | Participant |
| Jafral, Biotehnoloske Raziskave Inrazvoj, Doo | Ljubljana | Slovenia | Participant |
| The University of Reading | Reading | United Kingdom | Participant |
| University of Leicester | Leicester | United Kingdom | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI